Transcode Therapeutics Inc
Change company Symbol lookup
Select an option...
RNAZ Transcode Therapeutics Inc
PTON Peloton Interactive Inc
ETR Entergy Corp
ACMR ACM Research Inc
RGAGX American Funds The Growth Fund of America® Class R-6
ATRC AtriCure Inc
CTRA Coterra Energy Inc
CINF Cincinnati Financial Corp
ATOM Atomera Inc
IEAWW Infrastructure and Energy Alternatives 27 March 2023 *W EXP 03/27/2023
Go

Health Care : Biotechnology |
Company profile

TransCode Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for treating metastatic disease. The Company’s development pipeline includes TTX-MC138, TTX-siPD-L1 and TTX-RIGA, TTX-siLIN28B, and TCD-miR10b. The Company has developed a modular, iron oxide nanoparticle-based nanocarrier system for the delivery of RNA therapeutics to tumors. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include two solid tumor programs such as TTX-siPDL1, a small interfering RNA (siRNA)based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLin28b, a siRNA-based inhibitor of RNA-binding protein LIN28B. Its TTX platform is modular by design, both at the level of the core nanoparticle and at the therapeutic loading.

Closing Price
$1.26
Day's Change
-0.0008 (-0.06%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.26
Day's Low
1.26
Volume
(Light)
Volume:
1,659

10-day average volume:
56,738
1,659
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.